Serious Pulmonary Toxicity Secondary to Novel Hepatitis C Antiviral Therapy in a Liver Transplant Recipient

Mayo Clin Proc. 2015 Sep;90(9):1294-7. doi: 10.1016/j.mayocp.2015.06.015. Epub 2015 Jul 29.

Abstract

Historically, the treatment of hepatitis C virus infection has been difficult, but therapeutic options have improved markedly recently because of the development of novel antiviral therapies. These therapies have been well tolerated. We describe a patient who was receiving such therapy and had development of temporally related and histologically confirmed severe pulmonary toxicity. Pulmonary toxicity should be considered a potential serious complication of novel antiviral therapy for hepatitis C virus infection.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / adverse effects*
  • Female
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / surgery
  • Humans
  • Liver Transplantation / adverse effects*
  • Male
  • Pulmonary Fibrosis / chemically induced*
  • Pulmonary Fibrosis / drug therapy
  • Pulmonary Fibrosis / pathology
  • Risk Factors
  • Simeprevir / administration & dosage
  • Simeprevir / adverse effects
  • Sofosbuvir / administration & dosage
  • Sofosbuvir / adverse effects
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Simeprevir
  • Sofosbuvir